References
American Cancer Society. (2011). Global facts and figures (2nd ed.). Atlanta, GA: Author.
American Cancer Society. (2012). Cancer facts and figures 2012. Atlanta, GA: Author.
Bergh, J., Jönsson, P.E., Lidbrink, E.K., Trudeau, M., Eiermann, W., Brattström, D., … Henriksson, R. (2012). FACT: An open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. Journal of Clinical Oncology, 30, 1919-1925.
Berry, D.A., Cronin, K.A., Plevritis, S.K., Fryback, D.G., Clarke, L., Zelen, Z., … for the Cancer Intervention and Surveillance Modeling Network (CISNET) Collaborators. (2005). Effect of screening and adjuvant therapy on mortality from breast cancer. New England Journal of Medicine, 353, 1784-1792.
Bettelheim, F.A., Brown, W.H., Campbell, M.K., & Farrell, S.O. (2010). Organic chemistry. In F.A. Bettelheim, W.H. Brown, M.K. Campbell, & S.O. Farrell (Eds.), Introduction to organic and biochemistry (7th ed., pp. 307-322). Belmont, CA: Brooks/Cole, Cengage Learning.
Bishop, J.F., Dewar, J., Toner, G.C., Smith, J., Tattersall, M.H.N., Olver, I.N., … Canetta, R. (1999). Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. Journal of Clinical Oncology, 17, 2355-2364.
Bonneterre, J., Thürlimann, B., Robertson, J.F.R., Krzakowski, M., Mauriac, L., Koralewski, P., … von Euler, M. (2000). Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. Journal of Clinical Oncology, 18, 3748-3757.
Chia, S., Gradishar, W., Mauriac, L., Bines, J., Amant, F., Federico, M., … Piccart M. (2008). Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: Results from EFFECT. Journal of Clinical Oncology, 26, 1664-1670. doi:10.1200/JCO.2007.13.5822
Curtis, C., Shah, S.P., Chin, S.F., Turashvili, G., Rueda, O.M., Dunning, M.J., … Aparicio, S. (2012). The genomic and transcriptomic architecture of 2,000 breast tumors reveals novel subgroups. Nature, 486, 346-352. doi:10.1038/nature10983
Early Breast Cancer Trialists' Collaborative Group. (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet, 365, 1687-1717. doi:10.1016/S0140-6736(05)66544-0
Gradishar, W.J., Krasnojon, D., Cheporov, S., Makhson, A.N., Manikhas, G.M., Clawson, A., & Bhar, P. (2009). Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. Journal of Clinical Oncology, 27, 3611-3619. doi:10.1200/JCO.2008.18.5397
Gradishar, W.J., Krasnojon, D., Cheporov, S.V., Makhson, A.N., Manikhas, G.M., Clawson, A., & Iglesias, J. (2011). Nab-paclitaxel versus docetaxel for the first-line treatment of metastatic breast cancer: Final overall survival (OS) analysis of a randomized phase 2 trial [Poster 275]. Poster presented at the American Society of Clinical Oncology Annual Meeting, Chicago, IL.
Gradishar, W.J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., … O'Shaughnessy, J. (2005). Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. Journal of Clinical Oncology, 23, 7794-7803. doi:10.1200/JCO.2005.04.937
Hausheer, F.H., Schilsky, R.L., Bain, S., Berghorn, E.J., & Lieberman, F. (2006). Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Seminars in Oncology, 33, 15-49. doi:10.1053/j.seminoncol.2005.12.010
Howlader, N., Noone, A.M., Krapcho, M., Neyman, N., Aminou, R., Altekruse, S.F., … Cronin, K.A. (Eds.). (2012).
SEER cancer statistics review, 1975-2009. Retrieved from
http://seer.cancer.gov/csr/1975_2009_pops09
Hurtig, J. (2010). Managing patients with advanced and metastatic breast cancer: Taxanes and epothilones. Clinical Journal of Oncology Nursing, 14, 313-323. doi:10.1188/10.CJON.313-323
Mouridsen, H., Gershanovich, M., Sun, Y., Pérez-Carrión, R., Boni, C., Monnier, A., … Bhatnagar, A. (2003). Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. Journal of Clinical Oncology, 21, 2101-2019. doi:10.1200/JCO.2003.04.194
Nabholtz, J.M., Falkson, C., Campos, D., Szanto, J., Martin, M., Chan, S., … Poulliart, P. (1993). Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: Results of a randomized, multicenter, phase III trial. Journal of Clinical Oncology, 21, 968-975.
O'Shaughnessy, J. (2005). Extending survival with chemotherapy in metastatic breast cancer. Oncologist, 10(Suppl. 3), 20-29. doi:10.1634/theoncologist.10-90003-20
Pachman, D.R., Barton, D.L., Watson, J.C., & Loprinzi, C.L. (2011). Chemotherapy-induced peripheral neuropathy: Prevention and treatment. Clinical Pharmacology and Therapeutics, 90, 377-387. doi:10.1038/clpt.2011.115
Paridaens, R.J., Dirix, L.Y., Beex, L.V., Nooij, M., Cameron, D., Cufer, T., … Therasse, P. (2008). Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. Journal of Clinical Oncology, 30, 4883-4890. doi:10.1200/JCO.2007.14.4659
Perey, L., Paridaens, R., Hawle, H., Zaman, K., Nolé, F., Wildiers, H., … Thürlimann, B. (2007). Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: Final results of phase II Swiss Group for Clinical Cancer Research trial (SAKK 21/00). Annals of Oncology, 18, 64-69. doi:10.1093/annonc/mdl341
Ribeiro, J.T., Macedo, L.T., Curigliano, G., Fumagalli, L., Locatelli, M., Dalton, M., … Goldhirsch, A. (2012). Cytotoxic drugs for patients with breast cancer in the era of targeted treatment: Back to the future? Annals of Oncology, 23, 547-555. doi:10.1093/annonc/mdr382
Schneider, B.P., Zhao, F., Wang, M., Stearns, V., Martino, S., Jones, V., … Sparano, J.A. (2012). Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer. Journal of Clinical Oncology, 20, 3051-3057. doi:10.1200/JCO.2011.39.8446
Von Minckwitz, G., Schwedler, K., Schmidt, M., Barinoff, J., Mundhenke, C., Cufer, T., … Loibl, S. (2011). Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. European Journal of Cancer, 47, 2273-2281. doi:10.1016/j.ejca.2011.06.021
Wicklin Gillespie, T. (2005). Implementation of the NCCN practice guidelines: Anemia and neutropenia. Advanced Studies in Nursing, 3, 300-309.